Real-World Metabolic Improvements in Women With and Without Polyendocrine Metabolic Syndrome via a Multidisciplinary Telehealth Care Platform
- Design
- Retrospective cohort · 919 participants · Mixed outcome
- Match to healthy normal-weight adults aged 55–75
- Different populationINDIRECT: all participants were women with BMI ≥ 25 (overweight or obesity), 557 of 919 with PMOS.
- Could weight loss explain it?
- Not applicableNot applicable for the GLP-1 result, which is weight loss itself; models adjusted for baseline values, age, BMI, race/ethnicity and follow-up time, not for weight change.
- Study tier
- Study tier 3LOW: a single retrospective EHR cohort; GLP-1 use was not randomised, its effect size is not reported, and several authors are tied to Allara Health.
- Assessment
- Version 4 · Two reviewers differed; settled by a recorded ruling · Oct 19, 2026
Study facts come from the paper. Population match, weight-loss explanation and study tier are our judgments, made against the reference group of healthy normal-weight adults aged 55–75.
This records study followed 919 women with a BMI of 25 or more who started care on a women's health telehealth platform, 557 of them with PMOS (formerly called PCOS). Over a mean of 9.6 months, weight fell by 4.9% and blood-sugar, liver and cholesterol markers improved across the group, with no difference by PCOS status after adjustment. GLP-1 receptor agonist use was associated with greater weight loss, though women on no medication also improved; the GLP-1 difference is not quantified, and this is an association, not proof of cause.
01Findings
What the study reported
- Drugs
- Glp-1 receptor agonists
- Dose
- various
- Comparator
- no-medication group
- Primary outcome
- change in weight, HbA1c, HOMA-IR, fasting insulin, fasting glucose, ALT, AST and total cholesterol from baseline to last measured value
- Effect
- whole cohort: HOMA-IR -14.0%, fasting insulin -15.6%, fasting glucose -13.0%, HbA1c -6.2%, ALT -21.2%, AST -25.5%, total cholesterol -8.0%, weight -4.9%; GLP-1 RA use associated with greater weight loss (no figure given); PCOS status not associated with differential improvement
- 95% confidence interval
- not reported in abstract
- Follow-up
- ≥ 6 months (mean 9.6 months)
- Adverse events
- not reported in abstract
- Limitations
- Retrospective electronic-record study without randomisation, using the last measured value; the GLP-1 comparison is secondary and unquantified in the abstract, and several authors are employed or paid by Allara Health.
Who was studied
- Sex distribution
- women only (919 women)
- Bmi min
- 25
- Obesity status
- required (overweight or obesity, BMI ≥ 25)
- Diabetes status
- not reported in abstract
- Cvd status
- not reported in abstract
- Ckd status
- not reported in abstract
- Metabolic syndrome
- mentioned
- Baseline condition
- women with BMI ≥ 25 starting multidisciplinary telehealth care, 557 with PMOS (formerly PCOS)
- Sample size
- 919
- Inclusion exclusion
- women with BMI ≥ 25 starting care in 2024 with ≥ 6 months follow-up
Study quality details
- Study design
- Retrospective cohort
- Sample size
- 919
- Randomization
- no
- Blinding
- n/a
- Comparator
- no-medication group
- Follow up duration
- ≥ 6 months (mean 9.6 months)
- Outcome type
- mixed
- Replication
- not assessed
- Consistency with other evidence
- not assessed
- Population applicability
- INDIRECT
- Statistical precision
- no CI reported; no effect size given for the GLP-1 comparison
- Risk of bias
- not assessed
- Funding conflicts
- unclear
- Peer review status
- yes
02Funding
Funding and conflicts
- Funding
- not reported in abstract
- Industry funded
- Unclear
- Manufacturer
- not stated in source
- Sponsor role
- not reported in abstract
- Author conflicts
- One author (H.G.H.) is Chief Medical Advisor at Allara Health, receives research funding and holds stock options; five authors are Allara Health employees and one received a consulting fee from Allara Health.
- Independent replication
- unknown
Funding is shown on every study and never used to score it.
04Source
The source, as retrieved
Abstract
[OBJECTIVE] To evaluate metabolic outcomes in women with and without Polyendocrine Metabolic Ovarian Syndrome (PMOS, formerly Polycystic Ovary Syndrome (PCOS))) receiving multidisciplinary care through a women's health telehealth platform that combines physician and registered dietitian support. [METHODS] Retrospective cohort analysis of 919 women with BMI ≥ 25 initiating care in 2024, with ≥ 6 months follow-up (mean 9.6 months). Participants included 557 with PMOS and 362 without. Outcomes extracted from the electronic health record (EHR) included change in weight, HbA1c, HOMA-IR, fasting insulin, fasting glucose, ALT, AST and total cholesterol between baseline and last measured value. Linear regression models adjusted for baseline values of each outcome, age, BMI, race/ethnicity and follow-up time. [RESULTS] Significant improvements were observed across all metabolic markers for the group overall: HOMA-IR (-14.0%), fasting insulin (-15.6%), fasting glucose (-13.0%), HbA1c (-6.2%), ALT (-21.2%), AST (-25.5%), total cholesterol (-8.0%) and weight (-4.9%). PCOS status was not associated with differential improvement in any outcome after adjustment. GLP-1 receptor agonist use was associated with greater weight loss; however, improvements were also observed in the no-medication group. [CONCLUSIONS] Women with PCOS achieved metabolic improvements equivalent to those without PMOS through a multidisciplinary telehealth model despite presenting with a more adverse metabolic profile at baseline.
Where this record came from
| Source | Retrieved | Identifier |
|---|---|---|
| pubmed | Oct 18, 2026 | 42872607 first ingestion |